Clin Osteol 2025; 30(2): 71-76

Osteoporosis and diabetes mellitusMain theme

Ludmila Brunerová
Diabetologické centrum, Interní klinika FNKV a 3. LF UK Praha

Diabetes mellitus is associated with increased risk of osteoporotic fractures although pathophysiologic mechanisms may differ. In accordance with recent ADA/IOF updated guidelines, specific assessment of fracture risk and screening of osteoporosis should be involved in standard management of patients with diabetes. In real clinical practice, however, insufficient attention is paid to bone health in patients with diabetes. Entire diagnostic and therapeutic approaches are (with some specifics) similar to those in general population, the main difference being the therapeutic threshold (antiosteoporotic treatment should be considered in T-skóre ≤ -2,0), with focus on good diabetes control, decreasing the risk of hypoglycaemia and microvascular complications and to antidiabetic medication in patients at high risk of osteoporosis and fractures.

Keywords: diabetes mellitus, osteoporosis, screening, therapy.

Published: June 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brunerová L. Osteoporosis and diabetes mellitus. Clinical Osteology. 2025;30(2):71-76.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 50 CZK
    will be unlocked 1.6.2026

    References

    1. Comprehensive medical evaluation and assessment of comorbidities (2024) standards of care in diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S5276.
    2. Ferrari S L, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018;29(12):25852596.
    3. Johnell O, Kanis JA, Odén A, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15(1):3842.
    4. Shen Q, Ma Y. Impact of diabetes mellitus on risk of major complications after hip fracture: a systematic review and metaanalysis. Diabetol Metab Syndr. 2022;14(1):51.
    5. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288(15):18891897.
    6. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a metaanalysis. Osteoporos Int. 2007;18(4):427444.
    7. Hough FS, Pierroz DD, Cooper C, Ferrari SL. IOF CSA Bone and Diabetes Working Group. Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur J Endocrinol. 2016;174(4):R12738.
    8. StarupLinde J, Støy J, Grinderslev PB, et al. Prevalence and risk factors for osteoporosis in type 1 diabetes - results from an observational study. Osteoporos Int. 2025;36(5):823831.
    9. Weber DR, Gordon RJ, Kelley JC, et al. Poor glycemic control is associated with impaired bone accrual in the year following a diagnosis of type 1 diabetes. J Clin Endocrinol Metab. 2019;104(10):45114520.
    10. Shah VN, Sippl R, Joshee P, et al. Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance. Osteoporos Int. 2018;29(3):733739.
    11. Dou J, Wang J, Zhang Q. Differences in the roles of types 1 and 2 diabetes in the susceptibility to the risk of fracture: a systematic review and metaanalysis. Diabetol Metab Syndr. 2021;13:84.
    12. Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495505.
    13. StarupLinde J, Hygum K, Harsløf. Type 1 diabetes and bone fragility: links and risks. Diabetes Metab Syndr Obes. 2019;12:25392547.
    14. Rubin MR, de Boer IH, Backlund JC, et al. Biochemical markers of bone turnover in older adults with type 1 diabetes. J Clin Endocrinol Metab. 2022;107(6):e2405e2416.
    15. Xu Y, Wu Q. Trends in osteoporosis and mean bone density among type 2 diabetes patients in the US from 2005 to 2014. Sci Rep. 2021;11:3693.
    16. Luo W, Li X, Zhou Y, et al. Correlation between bone mineral density and type 2 diabetes mellitus in elderly men and postmenopausal women. Sci Rep. 2024;14:15078.
    17. Raška I Jr, Rašková M, Zikán V, et al. Prevalence and risk factors of osteoporosis in postmenopausal women with type 2 diabetes mellitus. Cent Eur J Public Health. 2017;25(1):310.
    18. HoPham LT, Nguyen TV. Association between trabecular bone score and type 2 diabetes: a quantitative update of evidence. Osteoporos Int. 2019;30(10):20792085.
    19. Liu X, Chen F, Liu L, et al. Prevalence of osteoporosis in patients with diabetes mellitus: a systematic review and metaanalysis of observational studies. BMC Endocr Disord. 2023;23:1.
    20. Viggers R, StarupLinde J, Vestergaard P. Discrepancies in type of first major osteoporotic fracture and antiosteoporotic therapy in elderly people with type 2 diabetes mellitus: a retrospective Danish cohort study. Bone. 2023;171:116745.
    21. Li W, Xie S, Zhong S, Lan L. The synergistic effect of diabetes mellitus and osteoporosis on the allcause mortality: a cohort study of an American population. Front Endocrinol (Lausanne). 2024;14:1308574.
    22. Pan Q, Chen H, Fei S, et al. Medications and medical expenditures for diabetic patients with osteoporosis in Beijing, China: a retrospective study. Diabetes Res Clin Pract. 2023;206:110980.
    23. Napoli N, Conte C. Bone fragility in type 1 diabetes: new insights and future steps. Lancet Diabetes Endocrinol. 2022;10(7):475476.
    24. Napoli N, Chandran M, Pierroz D, et al. Mechanisms of diabetes mellitusinduced bone fragility. Nat Rev Endocrinol. 2017;13:208219.
    25. Brunerová L, Urbanová J, Brož J. Diamond: Diabetes u endokrinopatií a endokrinopatie u diabetu. Grada. 2023;210213.
    26. Jackuliak P, Kužma M, Payer J. Effect of antidiabetic treatment on bone. Physiol Res. 2019;68 Suppl 2:S107S120.
    27. FRAX kalkulátor [Internet]. Vydavatel Centre for Metabolic Bone Diseases, University of Sheffield, UK. [cited 2025-04-26]. Available from: https://frax.shef.ac.uk/FRAX/tool.aspx?lang=cz.
    28. Chen W, Mao M, Fang J, et al. Fracture risk assessment in diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:961761.
    29. Ferrari S, Eastell R, Napoli N, et al. Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone. 2020;134:115268.
    30. Leslie WD, Johansson H, McCloskey EV, et al. Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD Registry. J Bone Miner Res. 2018;33(11):19231930.
    31. Palička V, Rosa J, Pikner R, et al. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Novelizace 2023 [Internet]. [cited 2025-04-26]. Available from: https://smos.cz/wp-content/uploads/2023/12/doporucene_postupy_osteoporoza_2023.pdf
    32. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):21842192.
    33. Pan R, Zhang Y, Zhao Y. Trabecular bone score in type 1 diabetes: a metaanalysis of crosssectional studies. J Orthop Surg Res. 2023;18:794.
    34. Leslie WD, AubryRozier B, Lamy O, et al. TBS (trabecular bone score) and diabetesrelated fracture risk. J Clin Endocrinol Metab. 2013;98(2):602609.
    35. SMOS. Metodika realizace populačního programu časného záchytu osteoporózy v ČR [Internet]. 2023 [cited 2025-04-26]. Available from: https://smos.cz/wp-content/uploads/2023/05/metodika-screening-osteoporoza-v2-17-5-2023.pdf.
    36. SMOS. Doporučení diagnostiky a léčby osteoporózy. [Internet]. v přípravě pro publikaci 2025.
    37. Conway BN, Long DM, Figaro MK, et al. Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Res Clin Pract. 2016;115:4753.
    38. Johnston SS, Conner C, Aagren M, et al. Association between hypoglycaemic events and fallrelated fractures in Medicarecovered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:634643.
    39. Škrha J sn, Pelikánová T, Prázný M, et al. Doporučený postup péče o diabetes mellitus 2. typu 2020 [Internet]. [cited 2025-04-26]. Available from: https://www.diab.cz/wp-content/uploads/2025/03/2020-1-standardy_DM_aktual_2020.pdf
    40. Eastell R, Vittinghoff E, Lui LY, et al. Diabetes mellitus and the benefit of antiresorptive therapy on fracture risk. J Bone Miner Res. 2022;37(11):21212131.
    41. Ferrari S, Eastell R, Napoli N, et al. Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone. 2020;134:115268.
    42. Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the MORE Study. J Bone Miner Res. 2004;19(5):764772.
    43. Schwartz AV, Pavo I, Alam J, et al. Teriparatide in patients with osteoporosis and type 2 diabetes. Bone. 2016;91:152158.
    44. Langdahl BL, Silverman S, Fujiwara S, et al. Realworld effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies. Bone. 2018;116:5866.
    45. Ferrari S, Betah D, Feldman RG, et al. Romosozumab improves tissue thicknessadjusted trabecular bone score in women with osteoporosis and diabetes. J Clin Endocrinol Metab. 2025:dgae862.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.